JBS Delivers Record-Breaking Performance in 2025 Despite Challenged Global Protein Markets

JBS Delivers Record-Breaking Performance in 2025 Despite Challenged Global Protein Markets


Global meat processing powerhouse JBS has concluded 2025 with a resounding performance, driven by its diversified and multi-protein platform.

The company's Q4 results were marked by a revenue of $23 billion, achieved alongside an impressive EBITDA margin of 17.5%. This accomplishment builds upon the full-year revenue, which reached a record high of $86 billion with a consolidated EBITDA margin of 7.9%.

CEO Gilberto Tomazoni underscored the company's strength in navigating industry cycles and capturing structural growth in protein demand: "This scale and the diversity of our multi-protein and multi-geography platform remain our greatest strength, allowing JBS to navigate industry cycles or any disruption while capturing a structural growth in protein demand."

The company's performance was highlighted by several key regions. In Australia, JBS reported strong EBITDA growth and margin expansion, as well as top-line growth of 30% year-over-year in the fourth quarter. This success was fueled by the current imbalance between global supply and demand of beef, combined with solid profitability.

In Brazil, the company's beef business operated within a historical margin range, supported by strong export and steady domestic demand. The fourth quarter saw particularly robust sales growth of 26% year-over-year in this market, alongside improvements in livestock productivity.

The country recorded its highest-ever beef processing volume at around 42 million heads, reinforcing Brazil's growing role in the global supply chain. JBS' Friboi business delivered solid results with growth in both export and domestic sales, as well as increased volumes in key international markets like Mexico, Europe, and the United States.

Additionally, Seara strengthened its brand strategy by expanding high-value-added products and deepening relationships with clients through programs such as Friboi Mais. In the US, JBS' chicken business continued to thrive due to strong demand in both retail and food service sectors.

Pilgrim's delivered volume growth above the industry average in segments like case-ready and small birds, while also improving performance in the big birds segment through better yields, mix, and cost efficiency. The Just Bare brand surpassed $1 billion in retail sales, reflecting the strength of JBS' brand strategy and significant opportunity for future growth.

Read more

Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

In a groundbreaking fourth quarter earnings call, Bicara Therapeutics unveiled an array of remarkable achievements that catapulted the clinical-stage biotech company to unprecedented heights. Under the leadership of CEO Claire Mazumdar, the company has been diligently pioneering bifunctional antibodies for targeted tumor modulation. Their innovative approach combines tumor targeting with

By Julia Horowitz